Trial Profile

Phase Id Trial to Evaluate SHR6390 Combined With Pyrotinib in Patients With HER2 Positive Advanced Stage Gastric Carcinoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 24 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dalpiciclib (Primary) ; Pyrotinib (Primary)
Indications Colorectal cancer; Gastric cancer; Solid tumours
Focus Adverse reactions

Most Recent Events

21 Jan 2023 Results presented at the 2023 Gastrointestinal Cancers Symposium.
08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
12 Mar 2019 Planned End Date changed from 1 Aug 2019 to 1 Aug 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com